as 07-11-2025 11:38am EST
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Founded: | 2014 | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 125.4M | IPO Year: | 2019 |
Target Price: | $85.67 | AVG Volume (30 days): | 99.7K |
Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -9.44 | EPS Growth: | N/A |
52 Week Low/High: | $10.29 - $98.00 | Next Earning Date: | 08-12-2025 |
Revenue: | $4,821,000 | Revenue Growth: | N/A |
Revenue Growth (this year): | 65.08% | Revenue Growth (next year): | -65.30% |
KRRO Breaking Stock News: Dive into KRRO Ticker-Specific Updates for Smart Investing
GOBankingRates
a month ago
GOBankingRates
a month ago
GOBankingRates
a month ago
Yahoo Finance
a month ago
The Guardian
a month ago
Yahoo Finance Video
a month ago
Benzinga
a month ago
Reuters
a month ago
The information presented on this page, "KRRO Korro Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.